HC Wainwright Raises Tempus AI (TEM) Price Target to $68

On October 26, 2026, HC Wainwright raised its price target for Tempus AI, Inc. (NASDAQ: TEM) to $68 from $66 while maintaining a Buy rating. This update comes as the stock continues to trade closely to the new target level.

HC Wainwright's adjustment reflects a positive outlook on Tempus AI, which operates in the healthcare technology sector. The company's shares closed at $67.61 on October 23, 2026, and are currently trading at the same level as of October 26, indicating that the stock is about equal to the new target. However, it remains below the average analyst price target of $74.94, suggesting room for growth.

TEM Tempus AI, Inc.

$67.61 ▲ +8.42% year to date

1M 3M YTD

Daily close · Oct 23, 2026

Other Institutional Activity in Tempus AI

ARK Investment Management, LLC holds about 10,022,634 shares of Tempus AI, having increased its position by 415,048 shares. This stake is valued at approximately $677.7 million. Meanwhile, Baillie Gifford & Co has reduced its holdings by 459,284 shares, now owning 8,190,133 shares worth about $553.8 million. Other notable investors include Softbank Group Corporation and Sumitomo Mitsui Trust Group, which have maintained their positions with no recent changes.

Tempus AI, Inc. Stock Up 6.0%

Tempus AI shares are currently trading at $67.61, which is below its 50-day moving average of $68.99 but above its 200-day moving average of $56.81. The stock is also 27.6% below its 52-week high of $93.38, yet it is up 65.8% from its 52-week low of $40.77.

Recent Earnings

Tempus AI reported trailing twelve-month revenue of approximately $1.43 billion, showing a year-over-year revenue growth of 21.6%. The company is scheduled to announce its next earnings on November 2, 2026. Currently, Tempus AI has a negative net margin of 17.8% and a return on equity of -67.4%.

Insider Buying and Selling at Tempus AI, Inc.

Several insiders have sold shares of Tempus AI recently. On September 1, 2026, Officer Ryan Fukushima sold 30,846 shares valued at about $1.93 million. Director David R. Epstein sold 250 shares at an average price of $65.55 for a total of $16,388. Additionally, CEO Eric P. Finally, Officer Thomas Edward Schoenherr sold 10,281 shares at $85 for a total of $873,885.

Analysts Set New Price Targets

On October 12, 2026, Canaccord Genuity maintained its Buy rating on Tempus AI with a price target of $95. On October 14, JP Morgan also maintained a Neutral rating but increased its target to $70 from $45. Needham reiterated its Buy rating with a target of $75 on October 23, 2026. HC Wainwright's new target of $68 was set on the same day, alongside BTIG, which reiterated its Buy rating at a target of $80.

About Tempus AI

Tempus AI, Inc. is a healthcare technology company based in Chicago, Illinois. It focuses on integrating diagnostic capabilities with a robust analytics platform to support healthcare providers. This price target adjustment by HC Wainwright reflects the firm's confidence in Tempus AI's growth potential in the health information services sector.

Bottom Line

Investors should keep an eye on Tempus AI's upcoming earnings report on November 2, 2026. The stock's current trading level is closely aligned with the new target set by HC Wainwright, and the average analyst target indicates potential for growth as the company continues to expand its revenue base.